Crown Bioscience

Executive Summary

Crown Bioscience is a full-service contract research organization (CRO) specializing in translational oncology, with a strong focus on patient-derived models and multi-omics platforms. Founded in 2006 and headquartered in Cambridge, UK, the company provides comprehensive preclinical and clinical CRO services that accelerate oncology and immuno-oncology drug development. Its proprietary suite of patient-derived xenograft (PDX) models and in vivo pharmacology capabilities enables biopharma clients to de-risk drug candidates and improve translational success rates. The company also has expanding capabilities in metabolic disease research and drug delivery, positioning it as a versatile partner for complex therapeutic programs. With a reputation for scientific excellence and a robust pipeline of client projects, Crown Bioscience is a key enabler in the precision medicine era.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation PDX platform for immuno-oncology80% success
• H2 2026Major strategic partnership with top-20 pharma for oncology R&D65% success
• Q4 2026Expansion of metabolic disease service line with new in vivo models70% success